Switch to Accessible Site
Joseph F. Goldberg, M.D.
Research-Based Expertise in the Psychopharmacology of Mood Disorders



Joseph F. Goldberg, M.D., L.L.C.
(203) 854-9607

128 East Avenue
Norwalk, CT 06851

[email protected]

About Me

I am a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particuarly bipolar disorder and other forms of depression.  I spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine.  Presently I supervise and teach psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintain a private practice in Norwalk, CT.  My goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient.  

I have published over 180 original research publications in major psychiatric journals as well as 3 books on topics related to mood disorders, focusing on the use of anticonvulsant mood stabilizers and atypical antipsychotics, safety risks with antidepressants in bipolar disorder, management of drug side effects, features related to rapid cycling bipolar disorder, suicide risk in bipolar disorder, cognitive dysfunction in bipolar disorder, pharmacogenetics in bipolar disorder, comorbid psychiatric disorders in bipolar disorder, and the long-term functional course and outcome of bipolar disorder and depression.  I serve on the board of directors of the American Society for Clinical Psychopharmacology and have lectured nationlly and internationally at major scientific meetings and conferences, such as the American Psychiatric Association, the Society of Biological Psychiatry, the American Society for Clinical Psychopharmacology, the American College of Neuropsychopharmacology, the European College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologicum, the International Society for Affective Disorders, and the International Society for Bipolar Disorders.  

EDUCATION:

  • B.A., Behavioral Sciences, The University of Chicago
  • M.S., Neuroscience, The University of Illinois
  • M.D., Northwestern University Medical School
       

ACADEMIC APPOINTMENTS:

Clinical Professor of Psychiatry, The Mount Sinai School of Medicine, New York, NY

LICENSURE AND CERTIFICATIONS:

 

 

  • Diplomate, American Board of Psychiatry and Neurology (Psychiatry)
       
  • New York State and Connecticut Physicians' License

 

 

ADDITIONAL TRAINING:

  • Internship, psychiatry residency, Chief residency and research fellowship in psychopharmacology at the Payne Whitney Clinic, New York Presbyterian Hospital

PROFESSIONAL ACTIVITIES AND MEMBERSHIPS:

  • Member, Board of Directors, American Society for Clinical Psychopharmacology
  • Distinguished Fellow, American Psychiatric Association
  • Founding Fellow, International Society for Affective Disorders
  • Member, Society of Biological Psychiatry
  • Deputy Editor, Current Psychiatry
  • Editorial Board Member: the Journal of Clinical Psychiatry; Bipolar Disorders; Acta Neuropsychiatrica Scandinavica; Frontiers in Psychiatry; MedScape


HONORS AND AWARDS:

  • Listed in Best Doctors in America and Castle Connolly Top Doctors
  • Career Development Award, National Institute of Mental Health
       
  • New Investigator Award, New Clinical Drug Evaluation Unit, National Institute of Mental Health
  • Laughlin Fellow, American College of Psychiatrists
  • Young Investigator Award, National Alliance for Research in Schizophrenia and Depression (NARSAD)
       

 

 

RESEARCH PUBLICATIONS:

 

 

1.      Goldberg JF, Pollack ED. Neuronal overload in the developing anuran lateral motor column in response to limb removal and thyroid hormone interaction. J Comparative Neurology 283: 578-586, 1989.
 
2.      Fichtner CG, Grossman LS, Harrow M, Goldberg JF, Klein DN. Cyclothymic moodswings in the course of major psychiatric illness. Am J Psychiatry 146: 1149-1154, 1989.
 
3.      Wolpert EA, Goldberg JF, Harrow M. Rapid cycling in unipolar and bipolar affective disorders. Am J Psychiatry 147: 725-728, 1990.
 
4.      Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders: A naturalistic followup study. Arch Gen Psychiatry 47: 665-671, 1990.
 
5.      Grossman LS, Harrow M, Goldberg JF, Fichtner CG. Outcome of schizoaffective disorder at two long-term followups: Comparisons with schizophrenia and affective disorders. Am J Psychiatry 148: 1359-1365, 1991.
 
6.      Goldberg JF, Harrow M. Kindling in bipolar affective disorders: A longitudinal followup study. Biol Psychiatry 35: 70-72, 1994.
 
7.      Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: A longitudinal follow-up study. Am J Psychiatry 152: 379-384, 1995.
 
8.      Goldberg JF, Harrow M, Grossman LS. Recurrent affective syndromes in bipolar and unipolar mood disorders at follow-up. Br J Psychiatry 166: 382-385, 1995.
 
9.      Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar disorders under naturalistic follow-up conditions. Psychopharmacol Bull 32: 47-54, 1996.
 
10. Goldberg JF, Harrow M, Sands JR. Lithium therapy in the longitudinal course of bipolar disorder. Psychiatric Annals 26: 651-658, 1996.
 
11. Harrow M, Sands JR, Silverstein M, Goldberg JF. Outcome in schizophrenics and other psychotic patients: A multi-follow-up study. Schiz Bull 23: 287-303, 1997.
 
12. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. Rapid titration of mood stabilizers predicts remission from acute mixed or pure mania. J Clin Psychiatry 59: 151-158, 1998.
 
13. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. The association between recurrent suicidal ideation and remission from acute mixed mania. Am J Psychiatry 155: 1753-1755, 1998.
 
14. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 60: 733-740, 1999.
 
15. Goldberg JF, Garno JL, Kocsis JH, Leon AC, Portera L, Whiteside JE. Correlates of suicidal ideation in dysphoric mania. J Affect Disord 56: 75-81, 1999.
 
16. Harrow M, Herbener ES, Kaplan KJ, Goldberg JF, Martin EM, Silverstein ML. Are schizoaffective patients just good prognostic schizophrenia patients? A longitudinal study. Schizophrenia Research 36: 8-9, 1999.
 
17. Goldberg JF. Treatment of bipolar disorder. Psych Clin N Amer Ann Drug Therapy 7: 115-151, 2000.
 
18. Goldberg JF. New drugs in psychiatry. Emerg Med Clin N Amer 18: 211-231, 2000.
 
19. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. Qualitative differences in mixed versus pure mania. Compr Psychatry 4: 237-241, 2000.
 
20. Goldberg JF. Treatment guidelines: Current and future management of bipolar disorder.  J Clin Psychiatry, 61 (suppl 13): 12-18, 2000.
 
21. Harrow M, Green EM, Sands JR, Jobe TH, Goldberg JF, Kaplan KJ, Martin EM.  Thought disorder in schizophrenia and mania: impaired context and working memory. Schiz Bull 26: 879-891, 2000.
 
22. Goldberg JF. Bipolar disorder with comorbid substance abuse: Implications for pathophysiology, prognosis, and treatment. J Psychiatric Practice, 7: 109-122, 2001.
 
23. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry 158: 1265-1270, 2001.
 
24. Goldberg JF, Burdick KE. Cognitive side effects of anticonvulsants. J Clin Psychiatry 62 (suppl 14): 27-33, 2001.
 
25. Goldberg JF, Singer TM, Garno JM. Suicidality and substance abuse in affective disorders. J Clin Psychiatry 62 (suppl 25): 35-43, 2001.
 
26. Kupfer DJ, Chengappa KNR, Gelenberg AJ, Hirschfeld RMA, Goldberg JF, Sachs GS, Grochocinski VJ, Houck PR, Kolar AB. Citalopram treatment of bipolar depression. J Clin Psychiatry 62: 985-990, 2001.
 
27. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 63 (suppl 4): 42-45, 2002.
 
28. Baker RW, Goldberg JF, Tohen M, Milton DR, Stauffer VL, Schuh LM. Olanzapine vs. placebo: mania improvement is unaffected by response to previous mood stabilizer therapy. Bipolar Disorders 4: 43-49, 2002.
 
29. Feldman D, Goldberg JF. A preliminary study of the relationship between clozapine-induced weight gain and menstrual irregularities in schizophrenic, schizoaffective, and bipolar women.   Ann Clin Psychiatry 14: 17-21, 2002.
 
30. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 63: 791-795, 2002.
 
31. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry 63: 985-991, 2002.
 
32. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V. Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 63: 1012-1019, 2002.
 
33. Burdick KE, Goldberg JF. Cognitive advantages of new anticonvulsants in treating a geriatric population. Clinical Geriatrics 10: 25-36, 2002.
 
34. Michaelis BH, Goldberg JF, Singer TM, Garno JL, Ernst CL, Davis GP. Characteristics of first suicide attempts in single versus multiple suicide attempters with bipolar disorder.  Compr Psychiatry 44: 15-20, 2003.
 
35. Goldberg JF, Cloitre M, Whiteside JE, Han H. An open-label pilot study of divalproex sodium for posttraumatic stress disorder related to childhood abuse. Curr Ther Res 64: 45-54, 2003.
 
36. Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 23: 182-192, 2003.
 
37. Goldberg JF. When do antidepressants worsen the course of bipolar disorder? Psychiatr Pract 9: 181-194, 2003.
 
38. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disorders 5: 407-420, 2003.
 
39. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle M-C, Lawson WB, Emsley RA, Zhang F, Baker RW, Risser RC, Namjoshi MA, Evans AR, Brier A. A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch Gen Psychiatry 60: 1218-1226, 2003.
 
40. Harrow M, Jobe TH, Herbener ES, Goldberg JF, Kaplan KJ. Thought disorder in schizophrenia: working memory and impaired context. J Nerv Ment Dis 192: 3-11, 2004.
 
41. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: A critical review.  Harvard Review of Psychiatry 12: 14-41, 2004.
 
42. Goldberg JF, Burdick KE, Endick CJ. A preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment resistant bipolar depression. Am J Psychiatry 161: 564-566, 2004.
 
43. Marangell LB, Martinez JM, Ketter TA, Bowden CL, Goldberg JF, Calabrese JR, Miyahara S, Miklowitz DJ, Sachs GS, Thase ME. Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disorders 6: 139-143, 2004.
 
44. Goldberg JF, Ernst CL. Clinical correlates of childhood and adolescent adjustment in adult patients with bipolar disorder. J Nerv Ment Dis 192: 187-192, 2004.
 
45. Michaelis BH, Goldberg JF, Davis GP, Singer TM, Garno JL, Wenze SJ. Dimensions of impulsivity-aggression associated with suicide attempts among bipolar patients: a preliminary study. Suicide & Life Threat Behav 34: 172-176. 2004.
 
46. Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: A 10-year follow-up. J Affect Disord 81: 123-131, 2004.
 
47. Ernst CL, Goldberg JF. Clinical features related to age at onset in bipolar disorder. J Affect Disord 82: 21-27, 2004.
 
48. Goldberg JF, Wankmuller MM, Sutherland KH. Depression with versus without manic features in rapid cycling bipolar disorder. J Nerv Ment Dis 192: 602-606, 2004.
 
49. Schneck CD, Miklowitz DJ, Calabrese JR, Allen MH, Thomas MR, Wisniewski SR, Miyahara S, Shelton M, Ketter T, Goldberg JF, Bowden CL, Sachs GS.  Phenomenology of rapid cycling bipolar disorder: Data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder. Am J Psychiatry 161: 1902-1908, 2004.
 
50. Goldberg JF, Fagin-Jones S. Recognizing and treating anxiety comorbidity in bipolar disorders. Psychiatric Annals 34; 874-884, 2004.
 
51. Goldberg JF, Wenze SJ, Singer TM, Steer RA, Beck AT. Content-specificity of dysfunctional cognitions for patients with bipolar mania versus unipolar depression: a preliminary study. Bipolar Disord 7: 49-56, 2005.
 
52. Garno JL, Goldberg JF, Ramirez PM, Ritzler B. Bipolar disorder with comorbid cluster “B” personality disorder features: impact on suicidality. J Clin Psychiatry 66: 339-345, 2005.
 
53. Garno JL, Goldberg JF, Ramirez PM, Ritzler BA. The impact of childhood abuse on the clinical course of bipolar disorder. Br J Psychiatry 186: 121-125, 2005.
 
54. Allen MH, Chessick CA, Miklowitz DJ, Goldberg JF, Wisniewski SR, Miyahara S, Calabrese JR, Marangell L, Bauer MS, Thomas MR, Bowden CL, Sachs GS.  Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. Suicide Life Threat Behav 35: 671-680, 2005.
 
55. Goldberg JF, Garno JL. Development of posttraumatic stress disorder in adult bipolar patients with histories of severe childhood abuse. J Psychiatr Res 39: 595-601, 2005.
 
56. Burdick CE, Endick JC, Goldberg JF. Assessing cognitive deficits in bipolar disorder: Are self-reports valid?  Psychiatry Res 136: 43-50, 2005.
 
57. Ettinger AB, Reed ML, Goldberg JF, Hirschfeld RMA. Prevalence of bipolar symptoms in epilepsy versus other chronic health disorders. Neurology 65: 535-540, 2005.
 
58. Goldberg JF, Harrow M. Subjective life satisfaction and objective functional outcome in bipolar and unipolar mood disorders: A longitudinal analysis. J Affect Disord 89: 79-89, 2005.
 
59. Goldberg JF, Garno JL, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr Opinion Psychiatr 7: 456-461, 2005.
 
60. Goldberg JF, Ghaemi SN. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disord 7 (suppl 5): 3-12, 2005.
 
61. Goldberg JF, Allen MH, Miklowitz DJ, Bowden CL, Endick CJ, Chessick CA, Wisniewski S, Miyahara S, Thase ME, Calabrese JR, Sagduyu K, Sachs GS. Suicidal ideation and naturalistic pharmacotherapy in bipolar outpatients: findings from the first       1000 patients in the Systematic Treatment Enhancement Program for Bipolar Disorder.  Psych Serv 56: 1534-1540, 2005.
 
62. Burdick KE, Goldberg JF, Harrow M, Malhotra AK, Faull RN. Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis 194: 255-260, 2006.
 
63. Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF, Sagduyu K, Miyahara S, Ketter TA. Overweight and obesity in bipolar disorders. J Psychiatr Res 40; 762-764, 2006.
 
64. Ernst CL, Bird SA, Goldberg JF, Ghaemi SN. The prescription of psychotropic medications for patients discharged from a psychiatric emergency service. J Clin Psychiatry 67: 720-726, 2006.
 
65. Klipstein KG, Goldberg JF. Screening for bipolar disorder in women with polycystic ovarian syndrome: A pilot study. J Affect Disord 91: 205-209, 2006.
 
66. Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, DeVeaugh-Geiss A, Thompson TR. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 59: 1061-1064, 2006.
 
67. Beck AT, Colis MJ, Steer RA, Madrak L, Goldberg JF. Cognitive checklist for mania-revised. J Psychiatr Pract 142: 333-340, 2006.
 
68. Iannuzzo RW, Jaeger J, Goldberg JF, Kafantaris V, Sublette ME. Development and reliability of the HAM-D/MADRS interview: an integrated depression symptom rating scale. Psychiatr Res 145: 21-37, 2006.
 
69. Goldberg JF, Ernst CE, Bird S. The disposition of patients with suicidal ideation from a psychiatric emergency service. Psych Serv 58: 561-565, 2007.
 
70. Gianfrancesco F, Rajagopalan K, Goldberg JF. Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications. Bipolar Disord 9: 252-261, 2007.
 
71. Burdick KE, Goldberg JF, Funke B, Kucherlapati R, Jaeger J, Malhotra AK.  COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord 9: 370-376, 2007.
 
72. Goldberg JF, Perlis RH, Ghaemi SN, Calabrese JR, Bowden CL, Wisniewski S, Miklowitz DJ, Sachs G, Thase ME. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings       from the STEP-BD. Am J Psychiatry 164: 1348-1355, 2007.
 
73. Vieta E, Goldberg JF, Mullen J, Vågerö M, Paulsson B. Quetiapine in the treatment of acute mania: target dose for efficacious treatment. J Affect Disord 100 (suppl1): S23-S31, 2007.
 
74. Truman CJ, Goldberg JF, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB, Thase ME, Sachs GS. Self-reported history of manic/hypomanic switch associated with antidepressant use: Data from the STEP-BD. J Clin Psychiatry 68: 1472-1479, 2007.
 
75. Burdick KE, Braga RJ, Goldberg JF, Malhotra AK. Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs 21: 971-981, 2007.
 
76. Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley M, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Clin Psychiatry 68: 1840-1844, 2007.
 
77. Goldberg JF, Bowden CL, Calabrese JR, Ketter TA, Dann RS, Frye MA, Suppes T, Post RM.  Six month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. Biol Psychiatry 63; 125-130, 2008.
 
78. Garno JL, Gunawardane N, Goldberg JF. Predictors of trait aggression in bipolar disorder. Bipolar Disord 10: 285-292, 2008.
 
79. Goldberg JF, Rosenquist KJ, Hsu DJ, Kelley ME, Ghaemi SN. Effectiveness of quetiapine in rapid cycling bipolar disorder: a preliminary study. J Affect Disord 105: 305-310, 2008.
 
80. Goldberg JF, King RS, Wenze SJ, Welker TM, Beck AT. Dysfunctional attitudes and cognitive schemas in bipolar manic and unipolar depressed outpatients: implications for cognitively based psychotherapeutics. J Nerv Ment Dis 196; 207-210, 2008.
 
81. Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH.  Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. J Clin Psychiatry 69: 1751-1757, 2008.
 
82. Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB, Calabrese JR, Nierenberg AA, Sachs GS. Mania symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry        166: 173-181, 2009.
 
83. Goldberg JF, Brooks JO, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 70: 155-162, 2009.
 
84. Goldberg JF, Garno JL. Age at onset of bipolar disorder and risk for comorbid borderline personality disorder. Bipolar Disord 11: 205-208, 2009.
 
85. Burdick KE, Gunawardane N, Goldberg JF, Halperin JM, Garno J, Malhotra AK.  Attention and psychomotor functioning in bipolar depression. Psychiatry Res 166: 192-200, 2009.
 
86. Frye MA, Yatham L, Ketter TA, Goldberg JF, Suppes T, Calabrese JR, Bowden CL, Bourne ES, Bahn RS, Adams B. Depressive relapse during lithium treatment associated with increased serum TSH: Results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr Scand 120: 10-13, 2009.
 
87. Goldberg JF, Chengappa KNR. Treatment of impaired cognition in bipolar disorder.  Bipolar Disord 11 (suppl 2): 123-127, 2009.
 
88. Goldberg JF, Calabrese JR, Saville BR, Frye MA, Ketter TA, Suppes T, Post RM, Goodwin FK. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. J Clin Psychiatry 70: 1273-1280, 2009.
 
89. Goldberg JF, McLeod LD, Fehnel SE, Williams VSL, Hamm LR, Gilchrist K. Development and psychometric evaluation of the Bipolar Functional Status Questionnaire (BFSQ). Bipolar Disord 12: 32-44, 2010.
 
90. Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, Burdick KE, Martinez-Aran A, Dittman S, Goldberg JF, Ozerdem A, Aydemir O, Chengappa KNR.  International Society for Bipolar Disorders – Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord 12: 351-363, 2010.
 
91. Berk M, Ng F. Dodd S, Goldberg JF, Malhi GS. Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. Psychiatr Clin Neurosci 64: 367-371, 2010.
 
92. Burdick KE, Goldberg JF, Harrow M. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up. Acta Psychiatr Scand 122: 499-506, 2010.
 
93. Perlis RH, Ostacher MJ, Goldberg JF, Miklowitz DJ, Friedman E, Calabrese J, Thase ME, Sachs GS. Transition to mania during treatment of bipolar depression.  Neuropsychopharmacology 35: 2545-2552, 2010.
 
94. Malhi GS, Chengappa KN, Gershon S, Goldberg JFHypomania: hype or mania? Bipolar Disord 12: 758-763, 2010.
 
95. Brooks JO III, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME. Safety and tolerability associated with second generation antipsychotic polytherapy in bipolar disorder: Findings from STEP-BD. J Clin Psychiatry 72: 240-247,       2011.
 
96. Perlis RH, Uher R, Ostacher M, Goldberg JF, Trivedi MH, Rush AJ, Fava M.  Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 68: 351-360, 2011.
 
97. Goldberg JF, Harrow M. A 15-year prospective follow-up of bipolar affective disorders: comparisons with unipolar nonpsychotic depression. Bipolar Disord 13; 155-163, 2011.
 
98. Goldberg JF, Altshuler LL, Frye MA, Keck PE Jr. Pharmacoeconomics of lithium and divalproex sodium in the treatment of bipolar disorder. Essential Psychopharmacology 2: 363-383, 1998.
 
99. Goldberg JF. Suicidality in mixed mania. Primary Psychiatry 6: 71-77, 1999.
 
100. Anderson T, Goldberg JF, Harrow M. A review of medication side effects and treatment adherence in bipolar disorder. Primary Psychiatry 11; 48-54, 2004.
 
101. Nnadi CU, Goldberg JF, Malhotra AK. Pharmacogenetics in mood disorder. Curr Opinion Psychiatry 18: 33-39, 2005.
 
102. Citrome L, Goldberg JF. The many faces of bipolar disorder: How to tell them apart.  Postgrad Medicine 117: 15-23, 2005.
 
103. Citrome L, Goldberg JFCommentary: Bipolar disorder is a potentially fatal disease.  Postgrad Medicine 117: 9-11, 2005.
 
104. Goldberg JF, Garno JL, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr Opinion Psychiatr 7: 456-461, 2005.
 
105. Nnadi CU, Goldberg JF, Malhotra AK. Genetics and psychopharmacology: prospects for individualized treatment. Essential Psychopharmacology 2005; 6: 193-208.
 
106. Geller R, Goldberg JF. A review of evidence-based psychotherapies for bipolar disorder. Primary Psychiatry 14: 59-69, 2007.
 
107. Goldberg JF. What psychotherapists should know about pharmacotherapies for bipolar disorder. J Clin Psychol 63: 475-490, 2007.
 
108. Goldberg JF. What constitutes evidence-based pharmacotherapy for bipolar disorder? J Clin Psychiatry 68: 1982-1983, 2007.
 
109. Goldberg JF, McElroy SL. Bipolar mixed episodes: characteristics and comorbidities. J Clin Psychiatry 68: e25, 2007.
 
110. Goldberg JF. What constitutes evidence-based pharmacotherapy for bipolar disorder? Part II: Complex presentations and clinical context (American Society of Clinical Psychopharmacology Corner). J Clin Psychiatry 69; 3: 495-496, 2008.
 
111. Goldberg JF. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. J Clin Psychiatry 69 (suppl 3): 11-19, 2008.
 
112. Goldberg JF. On being bipolar without being bipolar. J Psychopharmacol 28: 402-403, 2008.
 
113. Goldberg JF. The modern pharmacopeoa: a return to depressive realism? Bipolar Disord 10: 969-972, 2008.
 
114. Goldberg JF. Whither the academic psychiatrist? J Clin Psychiatry 69: 1792-1793, 2008.
 
115. Nasrallah HA, Black DW, Goldberg JF, Muzina DJ, Pariser SF. Diagnosing and managing psychotic and mood disorders. Ann Clin Psychiatry 20 (suppl 1): S1-S28, 2008.
 
116. Goldberg JF. Commentary: The role of divalproex plus olanzapine in outpatients with mixed episode bipolar I disorder. [Invited Editorial] J Clin Psychiatry 70: 1548-1550, 2009.
 
117. Goldberg JF. Myths and realities surrounding antidepressant use in bipolar disorder.  Current Psychiatry 9: 41-49, 2010.
 
118. Nasrallah HA, Goldberg JF, Correll CU; SAD Working Group. Differential diagnosis and therapeutic management of schizoaffective disorder. Ann Clin Psychiatry 22 (4 suppl 1): S1-S12, 2010.
 
119. Goldberg JF. Ruling in and ruling out “caseness” in the bipolar spectrum: implications for initial screening. Bipolar Disord 12: 539-540, 2010.
 
120. Goldberg JF. Expanding the bipolar construct while preserving its diagnostic integrity: are we keeping the baby or the bath water? World Psychiatry 10: 187-188, 2011.
 
121. Goldberg JF. A critical assessment of ultra-rapid cycling bipolar disorder. Current Psychiatry, in press.
 
122. Goldberg JF. Antidepressants: the scapegoat of poor outcome bipolar disorder? Aust N Z J Psychiatry, in press.
 
123. Grossman LS, Harrow M, Fudala J, Meltzer HY, Goldberg JF. Is outcome for schizoaffective patients more similar to that
for schizophrenia or affective disorders: In 
Grinker RR Sr., Harrow M (Eds): A Multidimensional Approach to Clinical Research in Schizophrenia, pp. 254-267. Springfield, IL: Charles C. Thomas, 1987.
 
124. Goldberg JF, Pollack ED. Thyroid hormone alters the progression of lateral motor column (LMC) neuronal loss in mid-larval Rana pipiens. Am Zoologist 27: 99A, 1987.
 
125. Goldberg JF, Pollack ED. Thyroxine-potentiated lateral motor column neuron number in limb-amputated Rana pipiens tadpoles. Soc Neurosci Abstracts: 117, 1988.
 
126. Fichtner CG, Grossman LS, Harrow M, Goldberg JF, Klein DF, Lensky DB.  Cyclothymia and the kindling hypothesis (letter). Am J Psychiatry 147: 818-819, 1990.
 
127. Fichtner CG, Grossman LS, Harrow M, Goldberg JF. Cyclothymic moodswings in major and minor psychiatric disorders (letter). Am J Psychiatry 148: 1104-1105, 1991.
 
128. Wolpert EA, Harrow M, Goldberg JF. Rapid cycling in affective disorders (letter). Am J Psychiatry 148: 1098-1099, 1991.
 
129. Goldberg JF, Sacks MH, Kocsis JH. Attenuation of response to serotonin reuptake inhibitors (letter). Am J Psychiatry 152: 954, 1995.
 
130. Goldberg JF, Leon AC, Garno JL, Kocsis JH. Anticonvulsants and lithium in mixed vs. pure bipolar disorders. Biol Psychiatry 39: 621-622, 1996.
 
131. Goldberg JF, Kocsis JH. Diagnosis and treatment of dysthymia: New findings. In Dunner DL (Ed.): Current Psychiatric Therapy II. Philadelphia: WB Saunders Co., pp. 232-238, 1997.
 
132. Goldberg JF, Harrow M. Poor outcome bipolar disorders. In Goldberg JF, Harrow M (Eds.): Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychiatric Press, pp. 1-19, 1999.
 
133. Goldberg JF, Kocsis JH. Depression in the course of bipolar illness. In Goldberg, Harrow M (Eds.): Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychiatric Press, pp. 129-147, 1999.
 
134. Goldberg JF, Keck PE Jr. Summary of findings on the course and outcome of bipolar disorders. In Goldberg JF, Harrow M (Eds.): Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychiatric Press, pp. 275-288, 1999.
 
135. Goldberg JF, Frye MA, Dunn R. Pramipexole in refractory bipolar depression (letter). Am J Psychiatry 156: 798, 1999.
 
136. Goldberg JF, Kocsis JH, Whiteside JE, Endick C. Loss of antidepressant response to SSRIs: Clinical and theoretical issues. Biol Psychiatry 45 (suppl 8S): 9S, 1999.
 
137. Goldberg JF, Sacks MH, Kocsis JH. Low-dose lithium augmentation of divalproex in geriatric mania (letter). J Clin Psychiatry 61: 304; 2000.
 
138. Goldberg JF. Spontaneous depression versus biphasic cycling and the treatment of bipolar depression (letter). Am J Psychiatry 158: 325-326, 2001.
 
139. Goldberg JF. Panic attacks associated with the use of topiramate (letter). J Clin Psychopharmacol 21: 461-462, 2001.
 
140. Goldberg JF, Burdick KE. Levetiracetam monotherapy in acute mania (letter). Am J Psychiatry 159: 148, 2002.
 
141. Goldberg JF, Ernst C. The economic and social burden of bipolar disorder. In Maj M (Ed) World Psychiatric Association Series: Evidence and Experience in Psychiatry, Vol. 5. London: John Wiley & Sons, Ltd., 2002, pp. 441-466.
 
142. Ghaemi SN, Goldberg JF, Ko JY, McNally EE. Quetiapine treatment of rapid-cycling bipolar disorder: an open prospective study. Int J Neuropsychopharmacol 5 (suppl 1): S110, 2002.
 
143. Berk M, Calabrese JR, Yatham L, Suppes T, Goldberg JF, Bowden CL. Lamotrigine controls bipolar depression without destabilizing mood. World J Biol Psychiatry 5 (suppl 1): 48, 2004.
 
144. Wagner Iannuzzo R, Jaeger J, Goldberg JF, Kafantaris V, Sublette ME. The HAM-D/MADRS Interview: an integrated depression symptom rating interview. Biol Psychiatry 55: 15S, 2004.
 
145. Goldberg JF, Burdick KE, Malhotra AK, Harrow M. Neurocognition as a stable endophenotype in mood disorders and schizophrenia. Biol Psychiatry 55: 91S-92S, 2004.
 
146. Goldberg JF, Malhotra AK, Calabrese JR, Bowden CL, Suppes T, Frye MA, Ketter TA. Weekly mood stability over 6 months with lamotrigine or placebo in bipolar rapid cycling. Biol Psychiatry 55: 141S-142S, 2004.
 
147. Burdick KE, Goldberg JF. Attention and psychomotor functions in bipolar depression.  Biol Psychiatry 55: 179S, 2004.
 
148. Farber GA, Goldberg JFOn combining norepinephrine and serotonin reuptake inhibitors for depression: Optimizing initial interventions (letter). Biol Psychiatry 56: 535, 2004.
 
149. Goldberg JF, Vieta E. Guest editorial: Selected papers from the Sixth International Conference on Bipolar Disorders: From Epidemiology to endophenotypes to advances in therapeutics. Bipolar Disord 9: 315-217, 2007.
 
150. Goldberg JF. In Session with Joseph F. Goldberg, M.D. (Interview). Primary Psychiatry 14: 42-46, 2007.
 
151. Goldberg JF. Antidepressants and manic symptoms: Reply to Dr. Rasmussen (letter). Am J Psychiatry 165: 264, 2008.
 
152. Nowakowska C, Sachs GS, Zarate CA Jr., Marangell LB, Calabrese JR, Goldberg JFKetter TA.  Increased rate of non-right handedness in patients with bipolar disorder [letter]. J Clin Psychiatry 69: 866-867, 2008.
 
153. Goldberg JF, Newman CF, Malhi GS, Miklowitz DJ. Improving psychotherapy practice and technique for bipolar disorder: lessons from cognitive neuroscience. In: Goldberg JF, Burdick KE (Eds): Cognitive Dysfunction in Bipolar Disorder: A Guide for
Clinicians. Washington, DC: American Psychiatric Press, pp. 113-136.
 
154. Goldberg JF. Cognitive adverse effects of psychotropic medications. In: Goldberg JF, Burdick KE (Eds): Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians. Washington, DC: American Psychiatric Press, pp. 137-158, 2008.
 
155. Goldberg JF, Young LT. Pharmacologic strategies to enhance neurocognitive function. In: Goldberg JF, Burdick KE (Eds): Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians. Washington, DC: American Psychiatric Press, pp. 159-194, 2008.
 
156. Vieta E, Martinez-Aran A, Goldberg JFCognition across the lifespan: Clinical implications for older adults with bipolar disorder. In: Goldberg JF, Burdick KE (Eds): Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians. Washington, DC: American Psychiatric Press, pp. 235-255.
 
157. Goldberg JF, Burdick KE. Summary and assessment recommendations for practitioners. In: Goldberg JF, Burdick KE (Eds): Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians. Washington, DC: American Psychiatric Press, pp.  257-271, 2008.
 
158. Goldberg JF. The role of antidepressants in managing bipolar II disorder. In Parker G (Ed): Bipolar II Disorder. Modeling, Measuring and Managing. Cambridge:  Cambridge University Press, 94-106, 2008.
 
159. Goldberg JF. Antidepressant prescribing and rapid cycling. [letter] Am J Psychiatry 165: 1048-1049; 2008.
 
160. Goldberg JF. How should research productivity be assessed in early career psychiatric researchers? Reply to de Leon. [letter] J Clin Psychiatry 70: 1328, 2009.
 
161. Goldberg JF. Relationship between substance abuse and switch from depression to mania in bipolar disorder [letter]. Am J Psychiatry 167: 868-869, 2010.

162. Malhi GS, Chengappa KN, Gershon S, Goldberg JF,  Hypomania: hype or mania? Bipolar Disord 2010; 12: 758-763.
 
163. Goldberg JF, Berk M. Rapid cycling bipolar disorder: phenomenology and treatment.  In Yatham L, Maj M (Eds). Bipolar Disorder: Clinical and Neurobiological Foundations. West Sussex, UK: Wiley-Blackwell, 2010, pp. 333-341.
 
164. Goldberg JF. The course of bipolar disorder in adulthood: a developmental perspective. In Miklowitz DJ, Cicchetti D (Eds): Bipolar Disorder: A Developmental Psychopathology Approach. New York: The Guilford Press, 2010, pp. 192-222.
 
165. Goldberg JF. Antidepressant use and risk for suicide attempts in bipolar disorder. [letter] J Clin Psychiatry 2011; 72: 1697.

166. Brooks JO 3rd, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME.  Safety and tolerability associated with second generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).  J Clin Psychiatry 2011; 72: 240-247.

167. Perlis RH, Uher R, Ostacher M, Goldberg JF, Trivedi MH, Rush AJ, Fava M.  Association between bipolar spectrum features and and treatment outcomes in outpatients with major depressive disorder.  Arch Gen Psychiatry 2011; 68; 351-360.

168. Goldberg JF, Harrow M.  A 15-year prospective follow-up of bipolar affective disorder: comparisons with unipolar depression.  Bipolar Disord 2011; 13: 155-163.
 
169. Goldberg JF. Akathisia after switching from branded to generic high-dose olanzapine.  J Clin Psychiatry 2012; 73: 497.

170. Goldberg JF.  Antidepressants: the scapegoat of poor outcome bipolar disorder? Austr N Z J Psychiatry 2012; 46: 302-305.

171. Goldberg JF. Lowering the diagnostic threshold for bipolar disorder: the wrong stuff? J Clin Psychiatry 2012; 73: 443-444.

172. Goldberg JF, Garakani A, Ackerman SH.  Clinician-rated versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance misuse.  J Clin Psychiatry 2012; 73: 1525-1530.

173. Sarapas C, Shankman SA, Harrow M, Goldberg JF.  Parsing trait and state effects of depression severity on neurocognition: evidence from a 26-year longitudinal study.  J Abnormal Psychology 2012; 121: 830-837.

174.  Goldberg JF.  A preliminary open trial of nefazodone added to mood stabilizers for bipolar depression.  J Affect Disord 2013; 144: 176-178.

175. Goldberg JF, Thase ME.  Monoamine oxidase inhibitors revisited: what you should know.  J Clin Psychiatry 2013; 74: 189-191.

 
176. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen W, Grunze H, Licht R, Post R, Berk M, Goodwin G, Sachs G, Tondo L, Findling R,
Youngstrom E, Tohen M, Undurraga J, 
Gonzales-Pinto A, Goldberg JF, Yildiz A, Altshuler L, Calabrese J, Mitchell P, Thase M, Koukopoulos A,
Colom F, Frye M, Malhi G, Fountoulakis K, Vazquez G, Perlis R, 
Ketter T, Cassidy F, Akiskal H, Azorin J-M, Valenti M, Hidalgo Mazzei D, Lafer B,
Kato T, Mazzarini L, Martinez-Aran A, Parker G, Souery D, Ozerdem A, McElroy S, Girardi P, Bauer M, Yatham L, Zarate Jr C, Nierenberg A,
Birmaher B, Kanba S, El-
Mallakh R, Serretti A, Rihmer Z, Young A, Kotzalidis G, MacQueen G, Bowden C, Ghaemi SN, Lopez-Jaramillo C,
Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam 
J, Hirschfeld R, Kapczinski F, Vieta E. The International Society for Bipolar Disorders
(ISBD) Task Force report on antidepressant use in bipolar disorders. Am J Psychiatry 170: 1249-1262, 2013.
 
177. Citrome L, Goldberg JF, Portland K. Placing transdermal selegiline for major depressive disorder into clinical context: Number needed
to treat, number needed to 
harm, and likelihood to be helped or harmed. J Affect Disord 151: 409-417, 2013.